BYM338 vs Meldonium

Head-to-head comparison of BYM338 (Bimagrumab (BYM338)) and Meldonium (3-(2,2,2-Trimethylhydrazinium)propionate) — benefits, dosing, side effects, research data, and where to buy.

Research Score

PropertyBYM338Meldonium
CategoryMuscle & PerformanceMuscle & Performance
Full NameBimagrumab (BYM338)3-(2,2,2-Trimethylhydrazinium)propionate
Molecular Weight~148 kDa146.19 Da
Half-Life~2-3 weeks~3-6 h
Amino AcidsN/AN/A
Typical Dose10-30 mg/kg IV in trials500-1000 mg/day in divided oral doses
RouteIntravenousOral/IV
Purity≥98%≥98%
Studies Count14070
Research StatusClinicalClinical

BYM338 Benefits

  • increased lean mass
  • functional strength support
  • reduced muscle wasting
  • metabolic body-composition shift

Meldonium Benefits

  • improves exercise tolerance
  • may reduce ischemic fatigue
  • supports metabolic efficiency
  • may aid recovery

BYM338 Dosing

IV infusion|10-30 mg/kg per study cycle|repeat every 4-12 weeks

Meldonium Dosing

500 mg orally daily|500 mg orally twice daily|500-1000 mg/day in divided doses

BYM338 Side Effects

  • muscle cramps
  • diarrhea/nausea
  • infusion reactions

Meldonium Side Effects

  • GI upset
  • headache
  • palpitations

Research Overview

BYM338

Clinical trials showed meaningful increases in lean mass, with mixed functional outcomes depending on population and endpoint. The antibody remains one of the best-documented receptor-blocking approaches to muscle anabolism in humans.

Meldonium

Clinical literature focuses on cardiometabolic support and exercise tolerance rather than direct anabolic effects. Any endurance benefit is thought to come from altered substrate handling and improved tolerance to stress.

Ready to buy?

Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.

Common Stacking Partners

BYM338 stacks with:

CreatineVitamin DLeucine

Meldonium stacks with:

CoQ10Creatine
actrII-blockermonoclonal-antibodysarcopenialean-massmetabolic-modulatorenduranceexercise-tolerancevo2-max